AstraZeneca to build £330 million Cambridge centre

Pharmaceutical company AstraZeneca has announced plans to build £330 million research centre and corporate HQ in Cambridge that will pave the way for new jobs in the construction industry.

The move is part of the company’s proposals to create strategic global R&D centres in the UK, US and Sweden to improve pipeline productivity and to establish AstraZeneca as a global leader in biopharmaceutical innovation.

Focusing on the company’s UK-based activities at the new centre in Cambridge, the pharmaceutical giant will build on AstraZeneca’s world-leading protein engineering capabilities already based in the city, expanding its operations and boosting employment across a range of industries in the area.

Chief executive of AstraZeneca, Pascal Soriot, said: “Our proposed investment is a clear signal of AstraZeneca’s long-term commitment to the UK and highlights the important role Cambridge plays internationally in bioscience research.

“The Government’s Life Sciences Strategy and the meaningful policies they have put in place in recent years to encourage investment help make Britain an attractive location for biopharmaceutical research and development.

“Cambridge, which boasts strong links with London-based research institutions, is a world-renowned bioscience hotspot that rivals the likes of San Francisco and Boston.

“In a world where partnerships and collaborations drive medical progress, becoming an integral part of the Cambridge ecosystem offers compelling advantages for AstraZeneca, giving us easier access to leading-edge academic and industry networks, scientific talent and valuable partnering opportunities.

“I believe that the investment we are announcing today greatly increases the chances that the next generation of innovative medicines will be invented and manufactured in Britain.”

What is your reaction to the £330 million plan to build a new research and corporate centre in Cambridge that will boot the construction industry and the trades? Share your thoughts by commenting here or raise your voice on our Facebook and Twitter pages.